Vivus reports bigger-than-expected 4th-qtr loss
Feb 25 (Reuters) - Vivus Inc's revenue for the first full quarter of selling its diet pill Qsymia fell short of analysts' estimates, and it posted a bigger-than-expected loss related to higher marketing expenses.
The company's fourth-quarter net loss rose to $56.7 million, or 56 cents per share, from $11.5 million, or 13 cents per share, a year earlier.
Net product revenue, reflecting sales of Qsymia, was $2 million in the fourth quarter, compared with $41,000 reported in the third quarter.
Vivus started generating revenue from the third quarter, when it began selling Qsymia.
- Tesla says in talks with BMW over car batteries, parts
- Exclusive: China ready to cut rates again on fears of deflation - sources
- Actor Dwight Henry eyed in New Orleans killing after arrest for theft
- China building South China Sea island big enough for airstrip: report
- Suicide bomber kills 45 at volleyball match in Afghanistan
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video